Skip to content

Ligand Pharmaceuticals

US · LGND #1920 by market cap Listed 1970
286.85 -0.09 -0.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.71% +1.57pp
Institutions
495 +10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund108.74%
Public Company4.02%
Individual/Insider2.23%
Government Pension Fund1.92%
Hedge Fund1.56%
Private Company0.90%
Family Office/Trust0.27%
Insurance Company0.24%

Top holders as of 2026-09-30

BlackRock 15.56% · 3.11M sh
Invesco Ltd. 5.87% · 1.17M sh
Vanguard Portfolio Management, LLC 5.56% · 1.11M sh
Janus Henderson Group plc 5.20% · 1.04M sh
Franklin Resources 4.56% · 912.31K sh
Vanguard Capital Management, LLC 4.35% · 869.48K sh
State Street Global Advisors 4.17% · 834.69K sh
FMR 3.49% · 697.18K sh
Congress Asset Management Company, LLP 3.29% · 658.56K sh
Geode Capital Management, LLC 2.93% · 586.81K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 18 buys · 32 sells

NameRoleStake
Todd Davis Chief Executive Officer 0.82%
Jason Aryeh Independent Director 0.54%
John Kozarich Independent Chairperson 0.21%
Stephen Sabba Independent Director 0.16%
Andrew Reardon Chief Legal Officer 0.16%
Octavio Espinoza Chief Financial Officer 0.14%
John LaMattina Independent Director 0.13%
Nancy Gray Independent Director 0.04%
Jason Haas Independent Director 0.02%
Martine Zimmermann Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 John Kozarich Independent Chairperson Intent to Sell (Form 144) -500 $325.00
2026-11-11 Martine Zimmermann Independent Director Intent to Sell (Form 144) -2,000 $318.17
2026-11-10 John Kozarich Independent Chairperson Intent to Sell (Form 144) -500 $317.32
2026-11-09 Jason Aryeh Independent Director Open Market Disposition -3,000 $319.99–320.20
2026-11-03 Jason Aryeh Independent Director Open Market Disposition -282 $319.99
2026-11-01 Jason Aryeh Independent Director Open Market Disposition -2,111 $317.74–320.49
2026-11-01 Jason Aryeh Independent Director Intent to Sell (Form 144) -700 $316.56
2026-11-01 Andrew Reardon Chief Legal Officer Derivative Exercise and Sale -5,000 $52.27–323.14
2026-10-29 Jason Aryeh Independent Director Intent to Sell (Form 144) -1,209 $318.60
2026-10-29 Jason Aryeh Independent Director Intent to Sell (Form 144) -202 $320.49
2026-10-01 Andrew Reardon Chief Legal Officer Automatic Disposition -4,660 $302.51–307.74
2026-10-01 Andrew Reardon Chief Legal Officer Derivative Exercise and Sale -340 $52.27–302.51
2026-09-21 Martine Zimmermann Independent Director Sale to Issuer -115 $298.50
2026-09-09 Martine Zimmermann Independent Director Open Market Disposition -1,200 $285.00
2026-09-02 Andrew Reardon Chief Legal Officer Automatic Disposition -5,000 $283.99–288.98
2026-08-11 Jason Haas Independent Director Open Market Disposition -1,000 $292.81
2026-08-11 Jason Haas Independent Director Derivative Exercise and Sale -6,138 $51.56–292.81
2026-08-11 Octavio Espinoza Chief Financial Officer Derivative Exercise and Sale -31,641 $52.84–292.07
2026-08-02 Andrew Reardon Chief Legal Officer Derivative Exercise and Sale -5,000 $52.27–292.82
2026-06-30 Andrew Reardon Chief Legal Officer Derivative Exercise and Sale -5,000 $52.27–317.15

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ligand Pharmaceuticals discussion 0 comments

Add a comment